PDCD1 and B-cell non-Hodgkin lymphoma: For instance, in a phase I trial in adults with relapsed or refractory (r/r) B cell non-Hodgkin’s lymphoma (B-NHL), a kind of virus-free CAR-T cells (PD1-19bblz), in which an anti-CD19 CAR sequence is specifically integrated at the PD1 locus using CRISPR–Cas9, exhibited promising efficacy with a manageable toxicity profile.